CA-SOURCE-PHOTONICS
7.12.2020 15:33:13 CET | Business Wire | Press release
Source Photonics, a leading vendor of optical connectivity products used in telecommunication systems and data communications networks, today announces the release of its new 100G ZR4 QSFP28 transceiver for 80km high-speed data center interconnects and routing applications. Leveraging the widely deployed 4 x 25G NRZ optics, 100G ZR4 QSFP28 is the latest addition to the company’s dominant 100G product lines among its leading 100/200/400G portfolio of single-mode transceivers for datacenter and routing applications.
Cloud traffic continues to drive data center growth and the industry requires cost-effective and high-bandwidth interoperable solutions. The Source Photonics 100G ZR4 QSFP28 is cost optimized and low power transceiver supporting 100G Ethernet for extended reach up to 80km transmission that provides point to point network connectivity solutions between data centers or central offices without the need to deploy either complicated, power hungry, and expensive coherent solution or legacy CFP/CFP2 interfaces. The 100G ZR4 QSFP28 alleviates the fiber shortage bottlenecks and enables hyperscale cloud operators to scale their network.
The transceiver is in QSFP28 form factor, the smallest for 100G 80km solution. It is fully compliant with the industry standard QSFP28 and related MSA described in the latest SFF-8665/8636 and digital diagnostic functions are available through an I2C interface. It also complies with IEEE 802.3 100GBASE-ZR4 related specifications. In addition, the module supports standard KR4 FEC (Forward Error Correction) baud rates which will help receive side detect and correct bit errors and improve the overall quality of the link. The 100G ZR4 QSFP28 transceiver is capable to operate over up to 80km point-to-point link without the need for optical amplification and dispersion compensation.
Source Photonics will showcase a product demonstration of the 100G ZR4 QSFP28 transceiver for 80km optical transmission in its virtual booth, in addition to live booth activities, and informative video content during the ECOC 2020 Virtual Exhibition on December 7 to 9.
Source Photonics is currently sampling its 100G ZR4 QSFP28 product, in addition to its latest 100G ER4 and 400G ER8 transceivers. Source Photonics is in full production of its other products for data center and routing applications such as 100G LR4/ER4 Lite, 100G DR1/FR1/LR1, and 400G DR4/FR4/LR4/LR8 transceivers.
For more information about Source Photonics and its product offering, please visit www.sourcephotonics.com .
About Source Photonics :
Source Photonics is a leading provider of innovative and reliable optical communications technology that enables communications and connectivity in datacenters, metro, and access networks. We add value to our customers by developing next-generation solutions that enable their growth by meeting the rapidly increasing demands of cloud infrastructure, wireless communications, routing, and fiber-to-the-premises applications worldwide. Source Photonics has key R&D and manufacturing facilities in California, Taiwan, Chengdu, and Jintan, China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201207005591/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom